Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525615 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 404
- Enrollment target
NCT01525615 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 404 participants.
The verdict
NCT01525615, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 404 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg; 5/5 µg) with placebo on exercise tolerance after 12 weeks of treatment in patients with COPD.
Interventions
- DEVICE Respimat inhaler
- DRUG tiotropium+olodaterol (low dose)
- DRUG tiotropium + olodaterol (high dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01525615
The ClinicalTrials.gov registry entry for NCT01525615 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Respimat inhaler is the first listed.
NCT01525615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01525615 about?
NCT01525615 is a clinical study titled "A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD". The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg; 5/5 µg) with placebo on exercise tolerance after 12 weeks of treatment in patients with COPD.
What is the current status of trial NCT01525615?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 404 participants. The study started on 2012-02. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01525615?
The interventions under investigation include: Respimat inhaler (DEVICE), tiotropium+olodaterol (low dose) (DRUG), tiotropium + olodaterol (high dose) (DRUG).
Who is sponsoring clinical trial NCT01525615?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.